Özbay-Haliloğlu Elif Nur, Tekin-Taş Zeynep
Department of Infectious Diseases and Clinical Microbiology, Sincan Research and Training Hospital, Ankara, Türkiye.
Infect Dis Clin Microbiol. 2025 Jun 26;7(2):133-142. doi: 10.36519/idcm.2025.508. eCollection 2025 Jun.
Laboratory parameters play a critical role in monitoring and prognosticating coronavirus disease 2019 (COVID-19). However, there there is limited research regarding the role of serial laboratory parameter monitoring in forecasting prognosis. This study aimed to investigate the trend of serial serum biomarker monitoring in patients with severe COVID-19 and determine its role in predicting the need for intensive care.
This retrospective single-center study included all patients aged 18 years and older diagnosed with severe COVID-19 and hospitalized between March 1 and November 30, 2021. Serial laboratory measurements - including lymphocyte count, platelet (PLT) count, C-reactive protein (CRP), aspartate aminotransferase (AST), alanine aminotransferase (ALT), D-dimer, ferritin, lactatedehydrogenase (LDH), and troponin I - were recorded on days 0, 2, 4, 6, and 8 from ward admission to intensive care unit (ICU) transfer. Patients who required ICU were compared to those who did not, regarding demographics, clinical features, and serial laboratory measurements. Receiver-operating characteristic (ROC) curves were generated for each serial laboratory parameter to assess its predictive value for ICU admission, and the area under the curve (AUC) was calculated.
A total of 773 patients were included, of whom 20.1% required ICU care. Significant differences were observed between the two groups in lymphocyte count, PLT, and troponin I across all measurements. CRP, D-dimer, and LDH showed significant differences between the groups on days 2, 4, 6, and 8. The AUC values of lymphocyte count, PLT, CRP, LDH, and troponin I increased in a time-dependent manner from day 0 to day 8, with an observed increase in statistical significance.
Dynamic monitoring of lymphocyte count, PLT, CRP, LDH, and troponin I was found to be valuable in predicting poor outcomes related to COVID-19. We believe that our study can assist clinicians in predicting ICU needs in patients with severe COVID-19 through widely accessible laboratory tests.
实验室指标在2019冠状病毒病(COVID-19)的监测和预后评估中起着关键作用。然而,关于连续实验室指标监测在预测预后方面的作用的研究有限。本研究旨在调查重症COVID-19患者连续血清生物标志物监测的趋势,并确定其在预测重症监护需求方面的作用。
这项回顾性单中心研究纳入了2021年3月1日至11月30日期间所有年龄在18岁及以上、被诊断为重症COVID-19并住院的患者。记录从病房入院到转入重症监护病房(ICU)第0、2、4、6和8天的连续实验室测量值,包括淋巴细胞计数、血小板(PLT)计数、C反应蛋白(CRP)、天冬氨酸转氨酶(AST)、丙氨酸转氨酶(ALT)、D-二聚体、铁蛋白、乳酸脱氢酶(LDH)和肌钙蛋白I。比较需要ICU治疗的患者与不需要ICU治疗的患者的人口统计学、临床特征和连续实验室测量值。为每个连续实验室指标生成受试者操作特征(ROC)曲线,以评估其对ICU入院的预测价值,并计算曲线下面积(AUC)。
共纳入773例患者,其中20.1%需要ICU护理。两组在所有测量中的淋巴细胞计数、PLT和肌钙蛋白I存在显著差异。CRP、D-二聚体和LDH在第2、4、6和8天两组之间存在显著差异。从第0天到第8天,淋巴细胞计数、PLT、CRP、LDH和肌钙蛋白I的AUC值呈时间依赖性增加,观察到统计学显著性增加。
动态监测淋巴细胞计数、PLT、CRP、LDH和肌钙蛋白I在预测与COVID-19相关的不良结局方面具有重要价值。我们认为,我们的研究可以通过广泛可用的实验室检查帮助临床医生预测重症COVID-19患者的ICU需求。